Research Article: Bibliometric Analysis of Global Trends in Remimazolam-Related Research Over the Past Years: Compared with Propofol
Introduction:
Remimazolam is a novel ultra-short-acting benzodiazepine derivative that acts on ?-aminobutyric acid receptors. As compared to midazolam, remimazolam is more rapidly hydrolyzed into an inactive metabolite (CNS ), has a shorter half-life and faster onset, offset by prolonged infusion, and reversal by flumazenil. As compared to propofol, remimazolam has superior clinical safety and is less likely to cause hypotension, cardiorespiratory depression, and pain upon injection. ,
Read more